Hybrid immunity from bivalent vaccination and prior infection enhances humoral and innate protection against Omicron XBB.1.16 and EG.5.1.1 variants in Japan - Scorecard - MDSpire
Advertisement
Hybrid immunity from bivalent vaccination and prior infection enhances humoral and innate protection against Omicron XBB.1.16 and EG.5.1.1 variants in Japan
Clinical Scorecard: Enhanced Humoral and Innate Immunity Against Omicron Variants XBB.1.16 and EG.5.1.1 in Japan Through Hybrid Immunity from Bivalent Vaccination and Previous Infection
At a Glance
Category
Detail
Condition
COVID-19
Key Mechanisms
Hybrid immunity enhances neutralizing activity and innate immune responses.
Target Population
Adults with ≥3 mRNA vaccine doses in Japan.
Care Setting
Immunological assessment in a serological survey.
Key Highlights
Hybrid immunity yields higher neutralization titers compared to vaccine-only groups.
Breakthrough infections are more common in individuals with low-vaccine-induced immunity.
Elevated IL-8 levels are associated with hybrid immunity and macrophage-neutrophil interactions.
Guideline-Based Recommendations
Diagnosis
Prior SARS-CoV-2 infection defined by PCR confirmation or seropositivity for N-IgG.
Management
Consider hybrid immunity in evaluating breakthrough infection risks.
Monitoring & Follow-up
Monitor neutralizing antibody titers and cytokine profiles in vaccinated individuals.
Risks
Breakthrough infections remain common despite vaccination, particularly with immune-evasive variants.
Patient & Prescribing Data
Adults with a history of vaccination and potential prior infection.
Bivalent mRNA vaccines may enhance hybrid immunity against emerging variants.
Clinical Best Practices
Encourage vaccination and monitor for breakthrough infections.
Assess both humoral and innate immune responses in vaccinated populations.
